a r t I C l e S The successive developmental stages of Schwann cell proliferation, axon sorting and myelination are regulated by a feed-forward cascade of transcriptional activators that ultimately upregulate a large number of genes encoding myelination-associated enzymes and myelin structural proteins [1] [2] [3] . Well-studied examples include the transcription factor Krox20, as illustrated by Krox20 mutant Schwann cells, which successfully sort axons but fail to generate or maintain myelin membranes 4, 5 , and the transcription factors Oct6 and Sox10, which are developmentally upstream of and directly interact with Krox20 to promote Schwann cell differentiation and myelination 6, 7 . Studies on constitutive and conditional Sox10 mutant mice reveal an essential role of this transcription factor in Schwann cell specification, lineage progression, differentiation, myelin formation and maintenance [8] [9] [10] [11] .
Most research on the genetic control of Schwann cell differentiation has concentrated on transcriptional activators that would generate positive feed-forward loops when uncontrolled. This raises the question how Schwann cell differentiation is properly balanced. Transcriptional repressors are plausible candidates. For example, the co-repressor Nab (also called NGFI-A-binding or Egr-binding protein) is essential for peripheral nervous system (PNS) myelination 12 . However, when associated with Krox20 this protein is a coactivator of myelin protein genes, and the significance of gene repression by Nab-Krox20 complexes in Schwann cells is unclear 13, 14 . The zincfinger protein Yin-Yang 1 (Yy1), an essential transcriptional inhibitor in myelinating oligodendrocytes 15 , has so far only been characterized as a transcriptional activator in the PNS, immediately upstream of Krox20 (ref. 16 ). Other transcription factors have been functionally identified as 'negative regulators' of myelination, but these include both transcriptional activators (for example, Sox2, c-Jun, Pax3, Notch-ICD) and inhibitors (Id2). While the most likely function of these factors is driving Schwann cell dedifferentiation after injury and in preparation for nerve repair 1 , their presence interferes with myelination and myelin maintenance.
Zinc-finger E-box-binding homeobox 2 (Zeb2, also known as Sip1 or Zfhx1b) is a widely expressed zinc-finger homeobox protein, originally identified by its binding to Smad1 (refs. 17, 18) . During epithelialto-mesenchymal transition, Zeb2 represses the transcription of several genes for cell adhesion molecules, such as E-cadherin (refs. 19-21) . In the CNS, newly born neurons express Zeb2 to downregulate signaling proteins that drive neurogenesis of adjacent precursors 22 . Zeb2 also regulates oligodendrocyte differentiation, as mutant cells fail to fully mature and make myelin 23 .
Like Sox10, Zeb2 is also detectable early in the neural crest lineage 24 and therefore a plausible candidate for transcriptional regulation in the Schwann cell lineage. In humans, mutations of SOX10 and ZEB2 have been associated with the clinically related Waardenburg syndrome type 4 and Mowat-Wilson syndrome, respectively 25 . For neural crest cells, direct interactions of Sox10 and Zeb2 proteins have even been proposed, but this is again difficult to reconcile with their respective roles as transcriptional activators and repressors 26 . Zeb2 a r t I C l e S is a canonical transcriptional repressor and, in neural-crest-derived immature Schwann cells, a candidate to 'release the brake' on differentiation that might be imposed by negative regulators, such as Sox2.
Here, we show that Zeb2 targets are indeed inhibitors of Schwann cell differentiation. Mice lacking Zeb2 specifically in this lineage show a complete arrest of Schwann cell maturation and exhibit a virtually complete absence of myelin. However, Zeb2-deficient Schwann cells survive in vivo and maintain axonal integrity. While Zeb2 is not required for adult myelin maintenance and axonal integrity, after injury Zeb2deficient Schwann cells fail to efficiently support nerve regeneration.
RESULTS
Zeb2 is expressed in Schwann cell development and after injury To explore Zeb2 expression by Schwann cells, we immunostained paraffin sections of mouse sciatic nerves at different developmental stages. Zeb2 was exclusively localized to cell nuclei. At embryonic day (E) 18.5, about 90% of Schwann cells were Zeb2-positive. At postnatal day (P) 10, roughly 70% of cells were Zeb2-positive, and in adult mice virtually all Schwann cells were Zeb2-negative ( Fig. 1a) .
To study the Schwann cell-specific function of Zeb2, we bred mice containing a loxP-flanked Zeb2 allele 27 to mice expressing Cre under control of the Desert hedgehog promoter, leading to recombination in the Schwann cell lineage between E11 and E13. 5 (refs. 9,28) , when most cells are at the precursor stage 29 . Loss of Zeb2 protein was confirmed by the absence of immunostaining ( Fig. 1a ) and by analysis of steady-state mRNA levels in sciatic nerve at age P1 (reduction to 14.1% of control; data not shown).
To determine possible Zeb2 re-expression in Schwann cells after acute sciatic nerve injury, we stained paraffin sections of the distal segment at different time points after a nerve crush ( Fig. 1b) . Zeb2 was detected as early as 6 h after injury (data not shown), and 80% of all cells could be stained 7 d after injury ( Fig. 1b) . On day 14 after crush, when remyelination is at its peak, about 50% of all Schwann cells still expressed Zeb2 (Fig. 1b) . Zeb2 was absent from distal stumps 28 d after crush (Fig. 1b) , and we could not detect Zeb2-positive cells in the contralateral uninjured nerve (Fig. 1b) . We conclude that Zeb2 expression is transient in peripheral nerves, preceding myelination in development and remyelination after acute nerve injury.
Zeb2 in Schwann cells is essential for axon sorting and myelination
Conditional mutants (Dhh-creøZeb2 loxP/loxP ) were born at the expected Mendelian ratio and phenotypically distinguishable from littermate controls by the second postnatal week, when they had reduced body size and developed ataxia and hind limb weakness (Supplementary Video 1) . The latter progressed with age but never led to complete hind limb paralysis. It was unexpectedly difficult to record compound muscle action potentials (CMAP) when electrically stimulating the sciatic nerve of conditional mutants compared a npg a r t I C l e S to heterozygous controls ( Fig. 1f) , which suggests major conduction blocks. However, Zeb2 conditional mutants had a normal life span and we only occasionally observed unexplained premature deaths.
To assess the developmental stage of Zeb2-deficient Schwann cells, we immunostained cross-sections from mutants and controls for Krox20 and Sox2 as prototype positive and negative regulators, respectively. We used S100β as a marker for both immature and mature Schwann cells. While Schwann cells in control mice robustly expressed Krox20 and S100β and were negative for Sox2, only a few Zeb2-deficient Schwann cells expressed Krox20 and S100β but about 30% were positive for Sox2 ( Fig. 1c-e ).
At P25, the sciatic nerves of mutant mice were thinner and more translucent than those of controls ( Fig. 2a,b ). Immunostaining of cross-sections for axonal β-tubulin (TuJ1) and myelin basic protein (Mbp) revealed closely packed, amyelinated axons in mutants but not in controls ( Fig. 2c,d) . Electron microscopy revealed that Zeb2-deficient mice lacked peripheral myelination and showed abnormal axon bundles, with Schwann cells engulfing larger groups of axons that also greatly varied in diameter ( Fig. 2e-i ). Within these bundles, interdigitating Schwann cell processes could be observed, but the majority of axons remained closely packed, resembling axons associated with immature Schwann cells in embryonic nerves ( Fig. 2i) . Most Schwann cells failed to establish one-to-one relationships with axons. We noticed that the basal lamina of Zeb2-deficient Schwann cells was often thin, discontinuous and not attached to the glial cell membrane, providing a plausible cause of failed axonal sorting 30 . Many Schwann cells also displayed redundant basal lamina loops ( Fig. 2g) .
At 1 year of age, peripheral axons had grown in diameter, but the overall pathology appeared unchanged ( Fig. 2j-l) . Compared to P25, the total Schwann cell number was unaltered in mutants ( Supplementary Fig. 1a ). Accordingly, the percentage of bromodeoxyuridine (BrdU)-positive (proliferating) cells did not differ between mutants and controls at E18.5, P10 and P25 ( Supplementary Fig. 1b ). This suggests that Zeb2-deficient Schwann cells exit the cell cycle normally and survive in the absence of myelination.
At all time points studied (including 1 year of age), we found no evidence for axonal degeneration, except for rare axonal swellings (data not shown). At 1 year, the total number of axons was unaltered in mutants compared to controls ( Supplementary Fig. 1c,d) . This suggests that Zeb2-deficient Schwann cells can support axon survival despite a dysmyelination that causes conduction blocks.
Mutant Schwann cells express negative regulators of differentiation
To further define the stage at which Zeb2-deficient Schwann cells arrest in development, we performed a transcriptome analysis of sciatic nerves at age P25. Steady-state levels of more than 700 mRNAs differed at least twofold in abundance between the two genotypes. The top 20 upregulated and downregulated genes are shown in Figure 3a .
We confirmed a subset of differentially regulated genes by quantitative real-time PCR, selecting promyelinating factors as well as negative regulators of myelination ( Fig. 3b,c) . As predicted from the phenotype of Zeb2-conditional mutants and the histological analysis, genes encoding myelin proteins were downregulated in mutants compared to controls ( Fig. 3c ). This was also the case for promyelinating factors of PNS myelination, such as Oct6 and Krox20 ( Fig. 3c) . Notably, Zeb2-deficient Schwann cells revealed the persistent expression of transcripts that are normally downregulated at this age (Fig. 3b) . This includes transcripts for negative regulators of Schwann cell differentiation (for example, Sox2, c-Jun, Id2) and markers defining immature Schwann cells (for example, Gfap). Zeb2-deficient Schwann cells also expressed very low amounts of S100β, a well-known marker of both immature and mature Schwann cells ( Fig. 3c) . In addition, we identified the Notch effector Hey2 as one of the most strongly (16.7 ± 1.4-fold) upregulated genes in our data set ( Fig. 3a,b) , as confirmed by quantitative PCR (qPCR). Other components of the Notch signaling cascade were also upregulated in our microarray analysis in mutants compared to controls, such as Notch1 (1.3-fold), Hes1 (1.6-fold) and Jagged1 (1.9-fold), arguing for persistently activated inhibitory Notch signaling in Zeb2-deficient Schwann cells. Using qPCR, we also found and confirmed highly elevated (13.4 ± 3.1-fold) expression of the endothelin receptor B (Ednrb) gene ( Fig. 3b) , encoding an efficient repressor of Schwann cell differentiation upon ligand binding 31 . Taken together, these facts suggest that Zeb2-deficient Schwann cells are arrested at an early developmental stage, with a very low expression of maturation factors and persistent (abnormal) expression of several negative regulators. npg a r t I C l e S
Zeb2-mediated repression of Ednrb and Hey2 in vivo
To determine whether Zeb2-mediated inhibition of inhibitors is also functionally relevant in vivo, we generated double mutant mice that combined Zeb2 deletion with the loss of either Ednrb or Hey2, for which loxP-flanked alleles were available 32, 33 . By crossbreeding, we obtained two genotypes (Dhh-creøZeb2 loxP/loxP øEdnrb loxP/loxP and Dhh-creøZeb2 loxP/loxP øHey2 loxP/loxP ), hereafter called Zeb2/Ednrb-dcKO and Zeb2/Hey2-dcKO. As phenotypic rescue was not expected with the loss of only one inhibitor, we searched for histological signs of improvement in these double mutants. We immunostained crosssections of sciatic nerves for Krox20. The number of labeled Schwann cell nuclei seen in Zeb2 loxP/loxP controls (36.7 ± 2.9 per section; Fig. 1c ) was strongly reduced in Zeb2 single mutants (to 6.0 ± 0.4), but increased significantly both in Zeb2/Ednrb-dcKO (to 19.9 ± 4.3) and in Zeb2/Hey2-dcKO (to 16.8 ± 2.9) sciatic nerves ( Fig. 4a,b) .
Fold change mut vs ctrl Brn2 P = 0.0006, t = 4.939481; Id2 P = 0.0004, t = 5.430061; Jun P = 0.008, t = 4.013638; Cdh2 P = 8.18 × 10 −6 , t = 8.972395; Pmp2 P = 3.5 × 10 −5 , t = 13.80419; Mpz P = 0.0001, t = 9.639648; Cnp1 P = 9.56 × 10 −5 , t = 11.06300; Krox20 P = 0.002, t = 4.786690; Oct6 P = 0.001, t = 6.015117; S100b P = 0.002, t = 4.855561; Ngfr P = 0.005, t = 3.579138; Erbb3 P = 0.0003, t = 6.287818; Cdh1 P = 0.0006, t = 5.291520; Itga4 P = 0.0003, t = 6.020152. Whiskers show minima and maxima; boxes extend from the first to the third quartiles with cross lines at the median. (d) Luciferase assays revealing Zeb2 gene dosage-dependent reduction of promoter activity of Sox2, Hey2 and Ednrb in S16 cells upon cotransfection with a Zeb2 expression plasmid. Each data point represents 1 independent experiment with 3 replicates ± s.e.m. with cross lines at the mean. Activity of lysates from cells cotransfected with the plasmid containing the respective promoter fragment and the empty pCMV5 plasmid was considered 100%. (n = 3 independent experiments with 3 replicates, one-sided Student's t-test of unpaired samples; versus 0 µg, from left to right: Sox2: P = 0.0005, t = 3.977938; P = 2.89 × 10 −11 , t = 15.28166; P = 1.46 × 10 −14 , t = 25.04342; Hey2: P = 0.162, t = 1.016833; P = 2.88 × 10 −6 , t = 6.631628; P = 2.16 × 10 −8 , t = 9.678931; Ednrb: P = 0.091, t = 1.392353; P = 2.48 × 10 −5 , t = 5.488391, P = 2.6 × 10 −6 , t = 6.688200; n.s., not significant; ***P < 0.001). (e) Promoter fragments with murine genomic localization and predicted Zeb2 binding sites (as used in d); TSS, transcription start site).
Schwann cell Zeb2 represses negative regulators of differentiation
To test whether Zeb2 acts as a repressor of relevant target genes, we performed luciferase gene reporter assays using the S16 Schwann cell line ( Fig. 3d) . Promoter regions of murine Sox2, Hey2 and Ednrb, each containing putative Zeb2 (E-box-like) binding sites 17 (Fig. 3e) , were cloned into the pGL2 luciferase plasmid and cotransfected with increasing amounts of a Zeb2 expression plasmid into S16 cells. This led to a significant dose-dependent downregulation of luciferase activity when compared to cotransfection with empty pCMV5 plasmid set to 100% (Fig. 3d) . To confirm the interaction of Zeb2 and its target genes at the DNA level, we performed chromatin immunoprecipitation (ChIP) experiments using pooled sciatic nerves from 1-d-old wild-type mice. By qPCR, we detected an enrichment of amplified fragments from the promoters of all three target genes (Sox2, Hey2 and Ednrb) that contained the canonical Zeb2 binding site, compared to control ChIP experiments without the Zeb2 antibody ( Supplementary  Fig. 2) . A DNA fragment of a bona fide target gene (Cdh1) lacking a Zeb2 recognition site was used as a negative control. npg a r t I C l e S At the morphological level, axon-Schwann cell units also appeared more mature in Zeb2/Ednrb-dcKO and Zeb2/Hey2-dcKO mice, at least when compared to the large and unsorted fiber bundles of Zeb2 single mutants (Fig. 4c) . The number of Remak-like (partially sorted) bundles with only 1-5 axons at age P25 ( Fig. 4d ) was higher in sciatic nerve cross-sections of double mutants (Zeb2/Ednrb-dcKO: 51.1 ± 18.85%; Zeb2/Hey2-dcKO: 55.2 ± 13.49%) than Zeb2 single mutants (Dhh-creøZeb2 loxP/loxP : 27.5 ± 6.1%). Thus, the lack of one negative regulator (downstream of Zeb2) improved the ability of Zeb2-mutant Schwann cells to initiate axon sorting. To further characterize Zeb2/ Ednrb-dcKO and Zeb2/Hey2-dcKO mutants, we analyzed target gene expression in sciatic nerves at age P25 ( Fig. 4e-g) . We did not detect any change in Sox2 or Hey2 mRNA in Zeb2/Ednrb-dcKO mice in comparison to controls (Zeb2 loxP/loxP mice in Fig. 4e and Zeb2 loxP/ loxP øEdnrb loxP/loxP mice in Fig. 4g ) However, Sox2 levels were significantly lower in Zeb2/Hey2-dcKO mice than in Dhh-creøZeb2 loxP/loxP mice and were comparable to Zeb2 loxP/loxP mice (Fig. 4e) . Ednrb was also significantly downregulated in comparison to Zeb2 loxP/loxP single mutants (Fig. 4f) .
Zeb2-deficient Schwann cells fail to efficiently support regeneration
Since Schwann cells re-expressed Zeb2 after an acute nerve injury ( Fig. 1b) , we asked whether the induction of Schwann cell dedifferentiation and peripheral nerve regeneration would be affected by the absence of Zeb2. To this end, we inactivated Zeb2 in Schwann cells of adult mice, using a tamoxifen-inducible Plp1-creERT2 driver line 34 . Recombination was induced at 6-8 weeks of age and efficient CreERT2 expression was confirmed on sciatic nerve cryostat sections using a Cre-sensitive tdTomato reporter allele 35 (Supplementary Fig. 3) .
When Plp1-creERT2øZeb2 loxP/loxP mice were analyzed 12 weeks after the last tamoxifen injection, sciatic nerve morphology and myelin sheath thickness appeared unaltered ( Supplementary Fig. 4a,b) . We then performed sciatic nerve crushes in mice 4 weeks after the last tamoxifen or vehicle injection. Footprint sequences of walking mice were used to monitor functional recovery. For histological analyses, animals were sacrificed 11, 28 and 56 days after sciatic nerve crush. In these experiments, mice from the three control groups functionally Fig. 5a ).
In physiological tests carried out 52 d after sciatic nerve crush, Zeb2 loxP/loxP control mice regained significant motor nerve conduction. We recorded a nerve conduction velocity (NCV) of about 18 ± 2.9 m/s, which is about 54% of the NCV of an unharmed contralateral nerve (33 ± 5.2 m/s), as determined in mice of either genotype. In contrast, Zeb2 conditional mutants maintained severe axonal conduction problems that did not allow us to measure any NCV (Fig. 5b,c) . Distal amplitudes (normal contralateral nerve: 29.8 ± 10.1 mV) were still reduced 52 d after crush injury in control mice (10.9 ± 4.4 mV) and undetectable in Plp1-creERT2øZeb2 loxP/loxP mutants, indicating a regeneration failure with irreversible conduction blocks (Fig. 5d) .
Indeed, when we immunostained sciatic nerve cross-sections for myelin (Mbp) and axons (TuJ1), virtually all fibers showed remyelination in control mice (Fig. 6a) , whereas in nerves of tamoxifen-induced Plp1-creERT2øZeb2 loxP/loxP mutants we observed large amyelinated fibers 8 weeks after injury (Fig. 6a) . We also analyzed remyelination by electron microscopy (Fig. 6b,c,e ). At 28 d and 56 d after crush injury, mutants exhibited significantly fewer remyelinated axons (Fig. 6d,e and Supplementary Fig. 5a) .
Interestingly, remyelinated axons in mutant (Plp1-creERT2ø Zeb2 loxP/loxP ) mice had the same myelin sheath thickness as in the three respective control groups (Zeb2 loxP/loxP mice lacking either Plp1-creERT2, tamoxifen or both), as measured by G-ratio analysis (Supplementary Fig. 5b) . Additionally, 56 d after crush we still observed remyelinating Schwann cells with myelin loops that were fewer in number and uncompacted (Fig. 6b) . Thus, the timing of Zeb2 re-expression after acute nerve trauma ( Fig. 1b) and the defect of remyelination in mutant mice strongly suggest Zeb2 is key to efficient Schwann cell response upon nerve injury.
Zeb2-deficient Schwann cells do not fully redifferentiate
To distinguish between alternative Zeb2 functions after nerve injury, we first studied sciatic nerves in tamoxifen-treated Plp1-creERT2ø Zeb2 loxP/loxP mice 3 d after transection, when Schwann cell dedifferentiation is at its peak. At this time, there was no significant difference in the number of residual myelin sheaths (1,650 ± 89 per section), when compared with vehicle-treated controls (1,785 ± 287), 3.0 mm distal to the transection site ( Fig. 7a,b) . We also detected no significant difference in the number of c-Jun-positive nuclei between two control groups and tamoxifen-treated mutants in distal segments of sciatic nerves 3 d after crush injury (Fig. 7c,d) .
Moreover, steady-state mRNA levels of Schwann cell dedifferentiation markers 1 such as c-Jun, Sox2 and Ngfr were comparable in mutants and controls in the distal stump ( Fig. 7e and data not shown), whereas myelination markers, such as Krox20 and Mpz, were downregulated in both mutants and controls compared to expression levels in the contralateral nerve (Fig. 7e) . Taken together, these results indicate that the early steps of Schwann cell dedifferentiation are not perturbed by the lack of Zeb2.
We next analyzed at a functional level the regenerative axon outgrowth of crushed sciatic nerves in conditional Zeb2 mutants and controls, using a pinch test. When tested 4 d after injury, deeply anesthetized mice of all three control groups showed a clear muscle a r t I C l e S reaction to a pinch of the sciatic nerve applied with a pair of forceps distal to the original crush site (Fig. 7f) . However, the distance at which a response could be elicited differed between genotypes, indicating more efficient axon outgrowth in all control groups (for example, 6.6 ± 0.8 mm in mice lacking Cre) compared to tamoxifentreated Zeb2 mutants (5.4 ± 1.3 mm). We hypothesized that reduced regenerative capacity is caused by poor Schwann cell differentiation. We therefore analyzed the distal stump of sciatic nerves at a late time point (56 d after crush), when control mice had fully recovered. Indeed, in Zeb2 mutants we could still detect a significant expression of dedifferentiation markers, such as Sox2 and Id2 (Fig. 7g) . Notably, Hey2 mRNA was only upregulated in mutant nerves ( Fig. 7g) (i.e., there was ectopic expression similar to that found in Zeb2-deficient Schwann cells at age P25). In contrast, Krox20 was downregulated only in mutant nerves (in comparison to the sustained expression in uninjured nerves), whereas Oct6 expression levels were similar in mutants and controls (Fig. 7g) . Taken together, these data indicate that Zeb2-deficient Schwann cells can dedifferentiate after injury, but fail to redifferentiate and provide efficient myelin repair.
DISCUSSION
We have identified an essential regulator of Schwann cell differentiation and peripheral myelination, the two-handed zinc finger/ homeodomain protein Zeb2. In contrast to previously described promyelinating transcription factors in the Schwann cell lineage, such as Oct6, Krox20 and Sox10, which activate the transcription of downstream factors and ultimately myelin-associated genes, Zeb2 is widely expressed 17 and a transcriptional repressor in Schwann cells. These findings are in agreement with the work of Wu et al. 36 (this issue).
Null mutant mice for Sox10, a gene which is, like Zeb2, expressed in the emerging neural crest, die embryonically with a lack of peripheral glia 8 . Later cell-specific deletion of Sox10 after Schwann cell specification (induced by Dhh-cre as in Zeb2 conditional knockout mice) leads to a similar developmental arrest in peripheral nerves with a lack of radial axonal sorting and virtual absence of myelin 9 .
Early arrest of Schwann cell maturation has been observed before in the context of chromatin remodeling. Mice in which Schwann cells lack Brg1, encoding a subunit of the Brg1/Brm-associated factors (BAF) chromatin-remodeling complex that is recruited by Sox10, develop a severe peripheral neuropathy and die prematurely 37 . Whereas the morphological defects of dysmyelination are strikingly similar in conditional Dhh-creøSox10, Dhh-creøBrg1 and Dhh-creø Zeb2 mutant mice, in Zeb2-deficient mice all Schwann cells survive. Despite the virtual absence of myelin and similarly severe neuropathy, conditional Zeb2-mutant mice have a normal life span, and Zeb2deficient Schwann cells support axon survival. Apparently the (ancestral) function of axon-ensheathing glial cells in providing metabolic support is maintained.
We also note that in Zeb2-deficient Schwann cells Sox10 mRNA itself is unaltered in abundance (data not shown). The transcriptional (co-)activator Sox10 is expressed throughout the Schwann cell lineage and directly binds to Oct6 and Krox20, potentially affecting a broader set of myelin-associated genes 6 , most likely including those that are required for survival and axonal metabolic support. We speculate that Schwann cell-mediated axonal support, which protects against complete paralysis and lethal breathing defects, is largely independent of Zeb2.
The developmental defect of conditional Zeb2-mutant mice is more severe than those of Oct6 or Krox20 mutants. Deletion of Oct6 causes only a transient arrest of Schwann cell differentiation after radial sorting; i.e., at the promyelin stage 38, 39 . Likewise, Schwann cells lacking Krox20 are able to sort axons but then completely fail to myelinate 4 .
Considering the unaltered levels of Sox10 mRNA in Zeb2-deficient Schwann cells and the more severe phenotype than that observed in Krox20-null mice, the most likely explanation why conditional a r t I C l e S Zeb2-mutants display very low expression of Krox20 and myelin protein genes is not the absence of promyelin factors but the persistent presence of maturation inhibitors (for example, Sox2, c-Jun, Ednrb) and the resulting developmental arrest. However, we cannot formally exclude the possibility that transcriptional activation of unknown target genes by Zeb2 (for example, in combination with unknown coactivators) also promotes Schwann cell differentiation in wild-type mice. Details of the transcriptional repression mechanisms by Zeb2 remain to be determined. One possibility is an interaction of Zeb2 with the histone deacetylase 1/2 (HDAC1/2)-nucleosome remodeling deacetylase (NuRD) co-repressor complex 40 in Schwann cells 36 .
With their radial sorting defect, conditional Zeb2 mutants resemble mutants of basal lamina signaling, such as double conditional mutants for beta-1 integrin and dystroglycan 41 or laminin 2 and 8 double knockout mice 42 . In conditional Zeb2 mutants, the basal lamina is thin, disorganized and often discontinuous. In dorsal root ganglion cocultures Zeb2-deficient Schwann cells failed to myelinate when provided with an artificial basal lamina (data not shown). Thus, basal lamina abnormalities are likely a secondary defect of Zeb2-deficient Schwann cells rather than the cause of dysmyelination.
We observed very low levels of S100b mRNA and S100β protein in Zeb2-deficient Schwann cells. This could mean that they are arrested even before reaching the immature developmental stage. However, this is unlikely, as we did not observe increased Schwann cell precursor proliferation or apoptosis.
The hierarchical relationship of the known transcription factors in the Schwann cell lineage is complex, owing in part to their broad temporal expression domains and changing molecular interactions, including positive feedback loops 3 . For example, Krox20 is activated in promyelinating Schwann cells by the positive regulators Oct6 and Sox10, which then collectively upregulate genes for myelin proteins and enzymes of the lipid biosynthesis pathway. How are these feedforward loops developmentally controlled? Our data on Zeb2 suggest the existence of several brakes in the system, with the loss of Zeb2 leading to continuous expression of developmental inhibitors that block axonal sorting and myelination. This group of negative regulators ; one-way ANOVA: P = 0.001, F 3,51 = 6.356539, ***P = 0.001). (g) After 56 d, levels of Sox2 and Id2 were strongly upregulated in injured nerves, but even more so in tamoxifentreated Plp1-creERT2øZeb2 loxP/loxP mutant mice. Hey2 levels were downregulated in injured control nerves, but highly upregulated in tamoxifentreated Plp1-creERT2øZeb2 loxP/loxP mutant mice. Krox20 levels remained low in nerves of mutants, while Oct6 was still upregulated to comparable levels in both genotypes. Each data point represents cDNA from 1 individual mouse run in triplicate ± s.d. with cross lines at the mean. Expression in the contralateral nerve was defined as 1.0. (Cre + loxP/loxP tamoxifen, n = 6; loxP/loxP tamoxifen, n = 5; contralateral, n = 5. Sox2: P = 0.0493, t = 2.271339; Id2: P = 0.0109, t = 3.197971; Hey2: P = 0.00072063, t = 8.963330; Krox20: P = 0.0062, t = 3.547758; Oct6: P = 0,2807, t = 1.147759; *P < 0.05; ***P < 0.001; n.s., not significant). npg a r t I C l e S overlaps but is not identical to other factors, such as c-Jun, known to drive programmed dedifferentiation of mature Schwann cells after nerve injury (see below). By expression profiling of peripheral nerves from Zeb2 mutant mice and by functional analysis of different promoter-reporter constructs, we identified Ednrb, Sox2 and Hey2 as target genes of Zeb2. We selected these genes from a much larger group of abnormally upregulated genes to show proof-of-principle for transcriptional repression by Zeb2, as well as for their putative inhibitory function in Schwann cell differentiation. Two of these genes had been previously associated with the Schwann cell lineage. Ednrb localizes to the plasma membrane of Schwann cell precursors and, upon binding of endothelin, delays the generation of immature Schwann cells both in vitro and in vivo. Indeed, Ednrb null mutant Schwann cells differentiate earlier than normal as shown by premature S100β expression 31 .
Sox2 is also a member of the Sry-related high-mobility-group-box family of transcription factors, but (unlike Sox10) widely expressed. Sox2 is downregulated early in Schwann cell development, coinciding with Krox20 expression 43 . Recently, it has been found that overexpression of Sox2 (a transcriptional activator) leads to persistent proliferation of Schwann cells and inhibits myelination, implicating Sox2 as a negative regulator of Schwann cell maturation in vivo (D.B. Parkinson, personal communication).
Hey2, a member of the hairy and enhancer-of-split-related basic helix-loop-helix transcription factor family, recruits histone deacetylases to repress transcription and acts as a downstream effector of Notch signaling 44 . Notch signaling serves as a timer in the generation of immature Schwann cells from precursors and is downregulated in cells that express Krox20. Additionally, Notch acts as an inhibitor of myelination in vitro and in vivo and is re-expressed in the distal stump of cut nerves 45 .
In our analysis, Hey2 was expressed at low levels in adult nerves and not activated during injury-induced Schwann cell dedifferentiation ( Fig. 7d and data not shown). We found Hey2 among the most highly upregulated mRNAs in sciatic nerves of Dhh-creøZeb2 loxP/loxP mice at age P25. Moreover, Hey2 was strongly expressed in adult mutants 8 weeks after nerve injury. In both cases, ectopic induction of Hey2 was a special feature of Zeb2-deficient Schwann cells. The physiological function of Hey2 in the Schwann cell lineage remains unknown. The conditional Dhh-creøHey2 loxP/loxP single mutants that we created in the course of our rescue experiments developed and myelinated normally (data not shown).
Thus, our findings suggest that negative regulatory proteins such as Sox2, Hey2 or Ednrb need to be downregulated early in development for Schwann cell differentiation, axonal sorting and myelination to proceed (Supplementary Fig. 6 ). Since Zeb2 itself is only transiently expressed, the downregulation of its target genes (inhibiting the inhibitors) most likely allows immature Schwann cells to overcome a developmental block, after which their further differentiation becomes Zeb2-independent. At least two of the identified Zeb2 target genes appear to contribute to this block (Hey2 and Ednrb), as evident from the partial rescue in corresponding double-mutant mice. One cannot assume that the phenotype of Zeb2 mutant mice can be rescued by introducing a second mutation into one gene for a (de-repressed) inhibitor. It is thus surprising that the additional deletion of either Ednrb or Hey2 was sufficient to markedly increase the number of Krox20-positive Schwann cells and morphological signs of sorting (more bundles with only 1-5 axons) in corresponding double-mutant mice. Experiments to find out whether these effects can be strengthened by targeting yet other genes and combining them in triple and quadruple mutants are important but beyond the scope of this first report.
Normally myelinated (adult wild-type) nerves lack both Zeb2 and its repressed target gene product(s), strongly suggesting that other factors are responsible for maintaining the brake on the expression of inhibitors, which would otherwise trigger dedifferentiation. The identity of these repressors is not known. At the same time, myelin maintenance has been shown to depend on continuous expression of the promyelinating factors Sox10 and Krox20 (refs. 5,11) .
Mutations of the human ZEB2 gene cause the rare Mowat-Wilson syndrome, characterized by moderate to severe mental retardation, brain abnormalities and variable features including Hirschsprung disease 25 . A reduced response to nociceptive stimuli has been found in people affected by Mowat-Wilson syndrome 46 , and lowered pain sensitivity and reduced number of nociceptive C-fibers have been demonstrated in Zeb2 heterozygous null mice 47 . However, it is unclear whether the reduced pain response seen in some people with Mowat-Wilson syndrome is a peripheral neuropathy or CNS phenotype 46 .
In the CNS, myelination by oligodendrocytes is controlled in many ways by negative regulators. Direct interactions with signaling molecules, such as bone morphogenetic protein (BMP), Notch ligand or Wnt proteins, can inhibit gene expression 48 . At the molecular level, chromatin remodeling and epigenetic silencing of transcriptional repressors also follows the inhibiting-the-inhibitors principle 49 . Zeb2 is also expressed in oligodendrocyte development, activated by Olig1 and Olig2, and is essential for CNS myelination as illustrated in Olig-creøZeb2 loxP/loxP mice 23 . Zeb2 levels are low in oligodendrocyte precursors and high in mature oligodendrocytes, where Zeb2 serves a dual role as both a repressor and also as a transcriptional activator of the Smad7 gene. The lack of Smad7 contributes to failed oligodendrocyte precursor differentiation and CNS dysmyelination in conditional mutant mice 23 . Thus, despite some phenotypic resemblances, Zeb2 serves different functions in PNS and CNS glial development.
When we deleted Zeb2 in Schwann cells of adult mice, we found a severe delay in regeneration and functional recovery after sciatic nerve crush injury. Even after 8 weeks, remyelination was not complete. Such a dramatic failure of myelin repair has been described in mice lacking the AP1 transcription factor c-Jun in Schwann cells 50 . However, in Jun mutant mice, the formation of a functional repair cell is impaired, while in Zeb2 conditional mutants, repair cells are generated but redifferentiation is inefficient. After sciatic nerve crush, Schwann cells lacking Jun fail to form regenerative tracts (bands of Büngner), which leads to a dramatic reduction of axon outgrowth 50 .
Here we detected only a minor reduction in axon outgrowth when tested 4 d after crush (Fig. 7e) . In Zeb2 conditional mutants (and similarly to Jun conditional mutants), if remyelination does initiate, myelin repair proceeds normally, as determined by G-ratio analysis. It has been hypothesized that the so-called repair cell marks dedifferentiation beyond the immature Schwann cell stage 50 . One analysis of injured nerves even revealed Schwann cell-derived melanocytes, normally a distinct sublineage of precursor cells 51 .
Repair cells that form after nerve injury and that are dependent on factors such as Zeb2 to fully activate the Schwann cell redifferentiation program are an important feature of nervous system function. Further characterization of genes involved in the plasticity of Schwann cells during development and in injury-related redifferentiation at adult stages will help to better understand the outcome of human demyelinating neuropathies and other diseases of the peripheral nervous system.
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